Faranak Kamangar, MD
Dermatology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kamangar’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A126556 · Current
Licensed to practise in California · since 2013 · expires 2027-05-31 · University of California, Davis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$125,867
Medicare paid this office $125,867 for 397 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 298 | $47,822 | $114 |
| Biopsy of related skin growth, first growth | 154 | $18,714 | $96 |
| Short return visit (20+ min) | 105 | $9,333 | $76 |
| Destruction of precancer skin growth, 1 growth | 136 | $9,272 | $52 |
| Destruction of skin growth, 1-14 growths | 45 | $6,024 | $112 |
See all 11 services
| Return visit (30+ min) | 298 | $47,822 | $114 |
| Biopsy of related skin growth, first growth | 154 | $18,714 | $96 |
| Short return visit (20+ min) | 105 | $9,333 | $76 |
| Destruction of precancer skin growth, 1 growth | 136 | $9,272 | $52 |
| Destruction of skin growth, 1-14 growths | 45 | $6,024 | $112 |
| Destruction of precancer skin growth, 2-14 growths | 108 | $3,258 | $7 |
| Biopsy of related skin growth, each additional growth | 42 | $2,829 | $52 |
| New patient visit (30+ min) | 33 | $2,776 | $84 |
| New patient visit (45+ min) | 18 | $2,614 | $145 |
| Application of light to destroy precancer skin growth | 11 | $1,683 | $129 |
| Short return visit | 13 | $522 | $37 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 368 | More than 84% of doctors who do this |
| Skin biopsy | 187 | More than 84% of doctors who do this |
Who their Medicare patients are
397 Original Medicare patients in 2024. Average age 76 · Women 58% · Also on Medicaid 5% · Health risk score 0.78. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 54% · Coronary heart disease 21% · Cancer 16% · Atrial fibrillation 16% · Chronic kidney disease 13% · Diabetes 11% · Depression 11% · Heart failure 6% · Stroke 4% · COPD 3%.
The office billed $472,561, Medicare allowed $170,475 and paid $125,867; for 1,704 services of 33 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 397 | 1,704 | 76 | 0.78 | $472,561 | $125,867 |
| 2023 | 364 | 1,672 | 76 | 0.80 | $388,367 | $110,018 |
| 2022 | 277 | 1,647 | 77 | 0.79 | $315,561 | $88,457 |
| 2021 | 334 | 2,033 | 76 | 0.78 | $332,180 | $102,166 |
| 2020 | 343 | 1,762 | 76 | 0.86 | $295,728 | $82,303 |
| 2019 | 424 | 1,744 | 75 | 0.79 | $304,253 | $83,989 |
| 2018 | 411 | 1,671 | 76 | 0.88 | $314,548 | $83,486 |
| 2017 | 364 | 1,093 | 76 | 0.94 | $222,242 | $62,698 |
| 2016 | 148 | 354 | 76 | 0.81 | $71,186 | $21,577 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 251 | $35,828 | $106 |
| Biopsy of related skin growth, first growth | 125 | $15,331 | $98 |
| Destruction of precancer skin growth, 1 growth | 134 | $9,356 | $51 |
| Short return visit (20+ min) | 94 | $9,122 | $78 |
| Destruction of skin growth, 1-14 growths | 55 | $8,704 | $115 |
| Destruction of precancer skin growth, 2-14 growths | 106 | $3,654 | $7 |
| New patient visit (30+ min) | 32 | $2,826 | $88 |
| Biopsy of related skin growth, each additional growth | 32 | $2,529 | $51 |
| Short return visit | 31 | $2,046 | $50 |
| New patient visit (45+ min) | 11 | $1,679 | $153 |
2022: 9 services
| Return visit (30+ min) | 198 | $25,948 | $104 |
| Biopsy of related skin growth, first growth | 100 | $11,246 | $95 |
| Destruction of precancer skin growth, 1 growth | 122 | $8,331 | $50 |
| Short return visit (20+ min) | 80 | $6,976 | $70 |
| Destruction of skin growth, 1-14 growths | 35 | $5,037 | $114 |
| Destruction of precancer skin growth, 2-14 growths | 98 | $4,244 | $7 |
| Biopsy of related skin growth, each additional growth | 25 | $1,782 | $52 |
| Short return visit | 30 | $1,491 | $44 |
| New patient visit (30+ min) | 11 | $845 | $77 |
2021: 11 services
| Return visit (30+ min) | 161 | $21,882 | $106 |
| Short return visit (20+ min) | 188 | $18,534 | $77 |
| Biopsy of related skin growth, first growth | 111 | $13,067 | $98 |
| Destruction of precancer skin growth, 1 growth | 145 | $10,967 | $51 |
| Destruction of skin growth, 1-14 growths | 54 | $8,398 | $115 |
| Destruction of precancer skin growth, 2-14 growths | 126 | $5,492 | $7 |
| Biopsy of related skin growth, each additional growth | 30 | $2,276 | $56 |
| Short return visit | 36 | $2,057 | $51 |
| Punch biopsy, first skin growth | 12 | $1,922 | $137 |
| New patient visit (45+ min) | 14 | $1,750 | $125 |
| New patient visit (30+ min) | 12 | $882 | $73 |
2020: 9 services
| Return visit (30+ min) | 151 | $15,154 | $84 |
| Biopsy of related skin growth, first growth | 110 | $11,836 | $94 |
| Short return visit (20+ min) | 139 | $10,610 | $61 |
| Destruction of precancer skin growth, 1 growth | 142 | $8,731 | $48 |
| Destruction of skin growth, 1-14 growths | 58 | $7,377 | $107 |
| Destruction of precancer skin growth, 2-14 growths | 120 | $3,863 | $6 |
| Biopsy of related skin growth, each additional growth | 42 | $2,968 | $53 |
| Short return visit | 76 | $2,787 | $32 |
| New patient visit (30+ min) | 22 | $1,982 | $90 |
2019: 12 services
| Return visit (30+ min) | 162 | $17,505 | $93 |
| Biopsy of related skin growth, first growth | 143 | $14,618 | $96 |
| Destruction of precancer skin growth, 1 growth | 144 | $8,307 | $49 |
| Short return visit (20+ min) | 103 | $7,528 | $64 |
| Short return visit | 140 | $7,138 | $42 |
| Destruction of skin growth, 1-14 growths | 30 | $3,991 | $111 |
| Destruction of precancer skin growth, 2-14 growths | 111 | $3,027 | $6 |
| Biopsy of related skin growth, each additional growth | 40 | $2,786 | $54 |
| New patient visit (30+ min) | 29 | $2,505 | $86 |
| New patient visit (45+ min) | 12 | $1,753 | $146 |
| New patient visit (15+ min) | 24 | $1,544 | $64 |
| Punch biopsy, first skin growth | 12 | $1,532 | $128 |
2018: 10 services
| Return visit (30+ min) | 169 | $16,414 | $79 |
| Biopsy of single growth of skin and/or tissue | 154 | $16,220 | $94 |
| Short return visit (20+ min) | 122 | $8,766 | $60 |
| Destruction of precancer skin growth, 1 growth | 133 | $8,205 | $49 |
| Destruction of skin growth, 1-14 growths | 37 | $5,473 | $105 |
| Short return visit | 121 | $5,165 | $37 |
| New patient visit (30+ min) | 38 | $3,001 | $79 |
| Destruction of precancer skin growth, 2-14 growths | 100 | $2,067 | $5 |
| Biopsy of each additional growth of skin and/or tissue | 27 | $1,100 | $30 |
| New patient visit (15+ min) | 22 | $964 | $44 |
2017: 10 services
| Return visit (30+ min) | 188 | $17,744 | $86 |
| Biopsy of single growth of skin and/or tissue | 108 | $10,076 | $91 |
| Short return visit (20+ min) | 104 | $6,716 | $57 |
| Destruction of precancer skin growth, 1 growth | 100 | $5,381 | $50 |
| Destruction of skin growth, 1-14 growths | 39 | $4,388 | $104 |
| New patient visit (30+ min) | 32 | $2,762 | $86 |
| New patient visit (45+ min) | 15 | $1,951 | $130 |
| Short return visit | 49 | $1,764 | $34 |
| Destruction of precancer skin growth, 2-14 growths | 71 | $1,433 | $5 |
| Biopsy of each additional growth of skin and/or tissue | 22 | $809 | $30 |
2016: 8 services
| Short return visit (20+ min) | 69 | $4,641 | $65 |
| Biopsy of single growth of skin and/or tissue | 37 | $3,541 | $96 |
| Short return visit | 45 | $2,163 | $41 |
| Return visit (30+ min) | 21 | $2,048 | $98 |
| Destruction of skin growth, 1-14 growths | 17 | $1,921 | $101 |
| Destruction of precancer skin growth, 1 growth | 35 | $1,790 | $48 |
| New patient visit (30+ min) | 11 | $1,007 | $92 |
| Destruction of precancer skin growth, 2-14 growths | 25 | $355 | $5 |
Drugs they prescribed that Part D paid
$17,378
Pharmacies billed $17,378 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 348) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
334 generic and 14 brand-name prescriptions · $17,378 in drug cost · 28 antibiotic prescriptions to 18 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Clobetasol Propionate | 22 | $1,466 | $67 |
| Fluorouracil | 24 | $1,447 | $60 |
| Tretinoin | 18 | $1,164 | $65 |
| Metronidazole | 12 | $692 | $58 |
| Triamcinolone Acetonide | 47 | $462 | $10 |
See all 11 drugs
| Clobetasol Propionate | 22 | $1,466 | $67 |
| Fluorouracil | 24 | $1,447 | $60 |
| Tretinoin | 18 | $1,164 | $65 |
| Metronidazole | 12 | $692 | $58 |
| Triamcinolone Acetonide | 47 | $462 | $10 |
| Ketoconazole | 32 | $429 | $13 |
| Doxycycline Hyclate | 18 | $272 | $15 |
| Nystatin | 12 | $185 | $15 |
| Valacyclovir | 18 | $165 | $9 |
| Hydrocortisone | 27 | $134 | $5 |
| Minoxidil | 11 | $30 | $3 |
Year by year
| 2024 | 348 | 172 | 0% (0) | 4% | $17,378 |
| 2023 | 295 | 146 | 0% (0) | 12% | $54,862 |
| 2022 | 254 | 105 | 0% (0) | 10% | $53,984 |
| 2021 | 352 | 141 | 0% (0) | 12% | $183,809 |
| 2020 | 302 | 143 | 0% (0) | 13% | $75,061 |
| 2019 | 266 | 150 | 0% (0) | 12% | $13,100 |
| 2018 | 338 | 152 | 0% (0) | 15% | $20,186 |
| 2017 | 240 | 122 | 0% (0) | 13% | $18,618 |
| 2016 | 243 | 122 | 0% (0) | 14% | $78,997 |
| 2015 | 355 | 128 | 0% (0) | None | $98,224 |
| 2014 | 227 | 106 | None | 19% | $61,693 |
| 2013 | 107 | 61 | 0% (0) | 20% | $25,947 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Clobetasol Propionate | 31 | $2,066 | $67 |
| Tretinoin | 16 | $1,154 | $72 |
| Ketoconazole | 49 | $874 | $18 |
| Doxycycline Hyclate | 13 | $409 | $31 |
| Triamcinolone Acetonide | 29 | $291 | $10 |
| Nystatin | 13 | $187 | $14 |
| Mupirocin | 12 | $132 | $11 |
| Hydrocortisone | 12 | $93 | $8 |
2022: 7 drugs
| Dupixent | 12 | $43,097 | $3,591 |
| Tretinoin | 11 | $1,428 | $130 |
| Ketoconazole | 47 | $903 | $19 |
| Clobetasol Propionate | 15 | $784 | $52 |
| Clindamycin Phosphate | 12 | $553 | $46 |
| Triamcinolone Acetonide | 23 | $247 | $11 |
| Nystatin | 13 | $204 | $16 |
2021: 11 drugs
| Dupixent | 12 | $40,948 | $3,412 |
| Clobetasol Propionate | 13 | $1,855 | $143 |
| Tretinoin | 12 | $1,505 | $125 |
| Ketoconazole | 44 | $1,199 | $27 |
| Clindamycin Phosphate | 21 | $674 | $32 |
| Triamcinolone Acetonide | 43 | $522 | $12 |
| Ciclopirox | 11 | $314 | $29 |
| Betamethasone Diprop Augmented | 12 | $289 | $24 |
| Minocycline | 12 | $215 | $18 |
| Mupirocin | 21 | $208 | $10 |
| Hydrocortisone | 18 | $145 | $8 |
2020: 7 drugs
| Dupixent | 11 | $36,505 | $3,319 |
| Fluorouracil | 14 | $1,464 | $105 |
| Clindamycin Phosphate | 18 | $702 | $39 |
| Ketoconazole | 24 | $679 | $28 |
| Triamcinolone Acetonide | 38 | $464 | $12 |
| Hydrocortisone | 32 | $287 | $9 |
| Mupirocin | 25 | $282 | $11 |
2019: 9 drugs
| Fluorouracil | 13 | $1,600 | $123 |
| Clobetasol Propionate | 14 | $1,133 | $81 |
| Betamethasone Dipropionate | 12 | $1,110 | $92 |
| Fluocinonide | 16 | $1,040 | $65 |
| Betamethasone Diprop Augmented | 14 | $620 | $44 |
| Triamcinolone Acetonide | 38 | $401 | $11 |
| Ketoconazole | 15 | $350 | $23 |
| Hydrocortisone | 20 | $157 | $8 |
| Mupirocin | 16 | $139 | $9 |
2018: 10 drugs
| Metronidazole | 16 | $1,528 | $95 |
| Fluocinonide | 25 | $1,438 | $58 |
| Ketoconazole | 48 | $1,409 | $29 |
| Clobetasol Propionate | 11 | $1,343 | $122 |
| Fluorouracil | 11 | $1,226 | $111 |
| Triamcinolone Acetonide | 60 | $818 | $14 |
| Ciclopirox | 12 | $330 | $27 |
| Mupirocin | 23 | $209 | $9 |
| Nystatin | 13 | $204 | $16 |
| Hydrocortisone | 19 | $189 | $10 |
2017: 5 drugs
| Clobetasol Propionate | 20 | $2,371 | $119 |
| Fluocinonide | 17 | $1,141 | $67 |
| Triamcinolone Acetonide | 36 | $707 | $20 |
| Ketoconazole | 25 | $368 | $15 |
| Mupirocin | 20 | $219 | $11 |
2016: 6 drugs
| Clobetasol Propionate | 25 | $5,067 | $203 |
| Fluorouracil | 12 | $1,509 | $126 |
| Clindamycin Phosphate | 13 | $786 | $60 |
| Triamcinolone Acetonide | 28 | $746 | $27 |
| Ketoconazole | 29 | $386 | $13 |
| Hydrocortisone | 15 | $114 | $8 |
2015: 7 drugs
| Clobetasol Propionate | 49 | $14,763 | $301 |
| Fluocinonide | 24 | $2,102 | $88 |
| Doxycycline Hyclate | 19 | $2,091 | $110 |
| Tretinoin | 17 | $1,994 | $117 |
| Triamcinolone Acetonide | 38 | $570 | $15 |
| Ketoconazole | 25 | $480 | $19 |
| Hydrocortisone | 11 | $124 | $11 |
2014: 4 drugs
| Fluocinonide | 25 | $1,432 | $57 |
| Clobetasol Propionate | 31 | $1,327 | $43 |
| Triamcinolone Acetonide | 22 | $391 | $18 |
| Hydroxyzine | 16 | $359 | $22 |
2013: 2 drugs
| Clobetasol Propionate | 21 | $639 | $30 |
| Triamcinolone Acetonide | 16 | $227 | $14 |
Money from drug and device companies
$693 in 2025
| 2025 | 12 | 24 | None | $693 |
| 2024 | 16 | 42 | $9,429 | $12,806 |
| 2023 | 4 | 7 | $3,654 | $3,912 |
| 2022 | 3 | 9 | None | $506 |
| 2021 | 1 | 1 | None | $26 |
| 2020 | 3 | 3 | None | $58 |
| 2019 | 4 | 4 | None | $74 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genzyme | Dupixent | $101 | 1 payment
|
| Sun Pharmaceutical Industries | None | $100 | 1 payment
|
| Galderma Laboratories L.P. | Nemluvio | $78 | 4 payments
|
| Organon | Vtama | $70 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $67 | 4 payments
|
| Ucb | Bimzelx | $57 | 2 payments
|
See all 24 published payments
| Galderma Laboratories L.P. | Meals · 2025-12-18 | Nemluvio | $14 |
| Sun Pharmaceutical Industries | Education · 2025-12-11 | None | $100 |
| Amgen | Meals · 2025-12-10 | Otezla | $22 |
| Regeneron Healthcare Solutions | Meals · 2025-12-04 | Dupixent | $17 |
| Ucb | Meals · 2025-12-02 | Bimzelx | $30 |
| Amgen | Meals · 2025-11-21 | Otezla | $20 |
| Organon | Meals · 2025-10-16 | Nexplanon | $16 |
| Galderma Laboratories L.P. | Meals · 2025-10-15 | Nemluvio | $24 |
| Regeneron Healthcare Solutions | Meals · 2025-10-14 | Dupixent | $14 |
| Arcutis Biotherapeutics | Meals · 2025-10-07 | Zoryve | $21 |
| Regeneron Healthcare Solutions | Meals · 2025-09-23 | Dupixent | $18 |
| Galderma Laboratories L.P. | Meals · 2025-09-17 | Nemluvio | $20 |
| Organon | Meals · 2025-09-16 | Vtama | $26 |
| Galderma Laboratories L.P. | Meals · 2025-09-09 | Nemluvio | $21 |
| Incyte | Meals · 2025-09-05 | Opzelura | $30 |
| Genzyme | Meals · 2025-09-05 | Dupixent | $101 |
| Ucb | Meals · 2025-06-06 | Bimzelx | $27 |
| Pfizer | Meals · 2025-05-26 | Cibinqo | $23 |
| Lilly USA | Meals · 2025-05-06 | Taltz | $23 |
| Arcutis Biotherapeutics | Meals · 2025-03-25 | Zoryve | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-09 | Sotyktu | $30 |
| Regeneron Healthcare Solutions | Meals · 2025-03-06 | Dupixent | $19 |
| Lilly USA | Meals · 2025-02-11 | Ebglyss | $25 |
| Organon | Meals · 2025-01-28 | Vtama | $29 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $12,806
| Janssen Biotech | Tremfya | $9,225 | 9 payments
|
| Genzyme | Dupixent | $2,114 | 2 payments
|
| Ucb | Bimzelx | $474 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $191 | 3 payments
|
| Dermavant Sciences | Vtama | $188 | 3 payments
|
| Abbvie | Rinvoq | $142 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $118 | 4 payments
|
| Eli Lilly and | Ebglyss | $101 | 1 payment
|
| Lilly USA | Taltz | $48 | 2 payments
|
| Incyte | Opzelura | $46 | 2 payments
|
| Janssen Scientific Affairs | Tremfya | $40 | 1 payment
|
| Amgen | Otezla | $31 | 1 payment
|
| Galderma Laboratories L.P. | None | $28 | 1 payment
|
| Arcutis Biotherapeutics | Zoryve | $21 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Cabtreo | $21 | 1 payment
|
| Pfizer | Eucrisa | $20 | 1 payment
|
2023: $3,912
| Regeneron Healthcare Solutions | Dupixent | $3,716 | 4 payments
|
| Dermavant Sciences | Vtama | $96 | 1 payment
|
| Ucb | Cimzia | $85 | 1 payment
|
| Pfizer | Cibinqo | $15 | 1 payment
|
2022: $506
| Regeneron Healthcare Solutions | Dupixent | $242 | 5 payments
|
| Abbvie | Rinvoq | $195 | 3 payments
|
| Galderma Laboratories L.P. | Aklief | $69 | 1 payment
|
2021: $26
| AbbVie | Skyrizi | $26 | 1 payment
|
2020: $58
| AbbVie | Skyrizi | $22 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $21 | 1 payment
|
| Sun Pharmaceutical Industries | Ilumya | $15 | 1 payment
|
2019: $74
| Ortho Dermatologics a division of Bausch Health US | Siliq | $19 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $19 | 1 payment
|
| AbbVie | Humira | $18 | 1 payment
|
| Lilly USA | Taltz | $18 | 1 payment
|
Professional record
- NPI
- 1114293800
- Licence
- CA A 126556California A126556: Current · expires 2027-05-31
- Trained
- University of California, Davis School of Medicine, 2012
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Student in a training program (390200000X)
- Mailing address
- 555 Middlefield Rd Ste 100, Palo Alto, CA, 94301
- NPI first listed
- 2012-03-27
- NPI last updated
- 2026-09-11
- NPI record certified
- 2026-09-11
This is when the NPI record was last certified, not a medical board exam.